within Pharmacolibrary.Drugs.ATC.A;

model A11CC04_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 4.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.06,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0021666666666666666,
    Tlag           = 600,            
    Vdp             = 0.15,
    k12             = 4.5,
    k21             = 4.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A11CC04_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Calcitriol is the hormonally active form of vitamin D3 (1,25-dihydroxycholecalciferol), used in the management of hypocalcemia and bone disorders associated with chronic renal failure, hypoparathyroidism, and some other conditions. It is approved and commonly used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics of calcitriol in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Levine, BS, &amp; Song, M (1996). Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. <i>Journal of the American Society of Nephrology : JASN</i> 7(3) 488–496. DOI:<a href=&quot;https://doi.org/10.1681/ASN.V73488&quot;>10.1681/ASN.V73488</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8704116/&quot;>https://pubmed.ncbi.nlm.nih.gov/8704116</a></p></li><li><p>Muindi, JR, et al., &amp; Trump, DL (2002). Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. <i>Clinical pharmacology and therapeutics</i> 72(6) 648–659. DOI:<a href=&quot;https://doi.org/10.1067/mcp.2002.129305&quot;>10.1067/mcp.2002.129305</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12496746/&quot;>https://pubmed.ncbi.nlm.nih.gov/12496746</a></p></li><li><p>Pierce, D, et al., &amp; Smyth, M (2011). The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 26(5) 1615–1621. DOI:<a href=&quot;https://doi.org/10.1093/ndt/gfq598&quot;>10.1093/ndt/gfq598</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20921291/&quot;>https://pubmed.ncbi.nlm.nih.gov/20921291</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A11CC04_1;
